Everolimus and Temozolomide in Advanced Gastroenteropancreatic Neuroendocrine Carcinoma (G3)

PHASE2CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

January 31, 2018

Study Completion Date

December 1, 2019

Conditions
Neuroendocrine Carcinoma
Interventions
DRUG

Everolimus , temozolomide

Trial Locations (1)

5021

Haukeland University Hospital, Bergen

All Listed Sponsors
collaborator

Skane University Hospital

OTHER

collaborator

Copenhagen University Hospital, Denmark

OTHER

collaborator

Rigshospitalet, Denmark

OTHER

collaborator

Uppsala University Hospital

OTHER

collaborator

Aarhus University Hospital

OTHER

collaborator

Sahlgrenska University Hospital

OTHER

collaborator

Ullevaal University Hospital

OTHER

lead

Haukeland University Hospital

OTHER

NCT02248012 - Everolimus and Temozolomide in Advanced Gastroenteropancreatic Neuroendocrine Carcinoma (G3) | Biotech Hunter | Biotech Hunter